FDA approves Genentech Enspryng as first at-home subcutaneous treatment for thyroid eye disease

The FDA has approved Genentech's Enspryng as the first at-home subcutaneous treatment option for adults with thyroid eye disease.

Enspryng (satralizumab-mwge), an interleukin-6 receptor inhibitor, can be administered subcutaneously with maintenance dosing every four weeks, expanding its use beyond its previously authorised indication.

The approval was supported by Phase III SatraGO-1 and SatraGO-2 studies, which provided evidence of improvements in eye bulging and double vision among patients with thyroid eye disease.

Field	Content
Article Type	Approvals
Drug Name	Enspryng
Generic Name	Satralizumab-mwge
Company	Genentech
Parent Company	Roche
Regulatory Authority	U.S. Food and Drug Administration
Regulatory Decision	Expanded indication approval
Approval Date	15 October 2026
New Indication	Thyroid eye disease in adults
Patient Population	Adults with thyroid eye disease
Therapeutic Area	Ophthalmology; autoimmune inflammatory disease
Drug Class	Interleukin-6 receptor inhibitor
Mechanism of Action	IL-6 receptor inhibition
Administration Route	Subcutaneous injection
Administration Setting	At-home administration
Maintenance Dosing	Every four weeks
Supporting Clinical Studies	Phase III SatraGO-1 and SatraGO-2
Reported Clinical Outcomes	Improvements in eye bulging and double vision
Approval Significance	First FDA-approved at-home subcutaneous treatment option for thyroid eye disease
Previous Indication	Previously approved for another indication; details not specified in supplied summary
Geography	United States
What Happened	The FDA expanded Enspryng's approval to include adults with thyroid eye disease.
Why It Matters	The approval introduces an at-home injectable treatment option for a condition that can cause substantial visual and functional impairment.
Clinical Evidence	Phase III SatraGO-1 and SatraGO-2 studies supported the decision; specific efficacy percentages were not provided in the supplied summary.
Potential Impact	At-home administration and four-week maintenance dosing may offer greater treatment flexibility for eligible patients.
Key Takeaway	Enspryng is now FDA-approved for adult thyroid eye disease as an at-home subcutaneous treatment.
What to Watch	US commercial availability, reimbursement, physician adoption, patient experience and longer-term treatment outcomes.
Primary Source	Genentech
Primary Source URL	https://www.gene.com/media/news-features/fda-approves-first-in-class-il-6r-inhibitor-as-the-first-and-only-at-home-subcutaneous-treatment-option-for-thyroid-eye-disease-ted
Relevant Date	15 October 2026

---

Discover how nuaxia can support your next medical education initiative:

• Find out more about our specialist services - Moore's Outcome Assessments, Educational Needs Assessments and Patient Impact Studies for the Medical Education sector

• Contact us on: support@nuaxia.com